Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms

Trial Profile

A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Amoxicillin; Ceftriaxone; Flucloxacillin; Nafcillin; Sulfamethoxazole; Teicoplanin; Trimethoprim; Vancomycin
  • Indications Gram-positive infections; Osteomyelitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Cubist Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 16 Jun 2020 Primary endpoint (Percentage of participants with clinical improvement in the 3 general categories of Pain, Inflammation, and Limb Function based on the Investigators overall assessment of severity of each of the symptom categories.)has not been met, as per Results published in the Pediatric Infectious Disease Journal
    • 16 Jun 2020 Results published in the Pediatric Infectious Disease Journal
    • 02 Jan 2017 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top